

Meningococcal Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands: Menomune[®], Menactra[®], and Menveo[®] • Inactivated, bacterial polysaccharide (Menomune[®]) • Inactivated, bacterial polysaccharide conjugate (Menactra[®] and Menveo[®]) • Contains thimerosal (only multidose Menomune[®]) and latex (stopper only for Menactra[®]) • See package insert
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: SC (Menomune[®]) and IM (Menactra[®] and Menveo[®]) - (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) • See package insert
Indications	<ul style="list-style-type: none"> • U.S. military basic trainees • Children at the 11-12 year of age visit or at subsequent visit • People who might be infected during an outbreak of certain types of meningococcal disease • Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as sub-Saharan Africa • Anyone who has a non-functioning spleen or whose spleen has been removed • Anyone who has terminal complement component deficiency (an immune system disorder) • People at occupational risk • College freshmen, especially those who live in dormitories • Menactra[®] or Menveo[®] are preferred, but Menactra[®] is only licensed for use in people 2-55 years of age and Menveo[®] in people 11-55 years of age
Administration Schedule	<ul style="list-style-type: none"> • Single dose
Booster	<ul style="list-style-type: none"> • Menomune[®] and Menactra[®]: <ul style="list-style-type: none"> • 5 years if 1st dose given at 7 years of age or older • 3 years if 1st dose given at 2 through 6 years of age • Menveo[®]: unknown at this time

Meningococcal Vaccine (*Continued*)

Contraindications	<ul style="list-style-type: none">• Serious allergic reaction to prior dose or vaccine component• Moderate or severe illness• Menactra® is only licensed for use in people 2-55 years of age (See package insert)• Menveo® is only licensed for use in people 11-55 years of age (See package insert)• Menomune® is not licensed for children younger than 3 months of age. Children 3 months to 2 years should receive this vaccine only under special circumstances. These children need 2 doses, 3 months apart. (See package insert)• History of Guillain-Barré syndrome (Menactra®)
Special Considerations	<ul style="list-style-type: none">• There have been reports of Guillain-Barré syndrome (GBS) after Menactra® but population-based increase of disease related to vaccine has not been documented• Menactra® and Menveo® have not been widely studied in pregnant women and should be given only if clearly indicated; OK to give Menomune®• See Storage and Handling Section
VIS: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf Pregnancy registry for Menactra®: 1-800-822-2463 (sanofi pasteur); Pregnancy registry for Menveo®: 1-877-311-8972 (Novartis); also notify VHC Networks for long-term support and follow-up	

FACTOID: High fever, headache, and stiff neck are common symptoms of meningitis in anyone age 2 years and older.

Source: <http://www.cdc.gov/meningitis/bacterial/faqs.htm>